<DOC>
	<DOCNO>NCT00180947</DOCNO>
	<brief_summary>This phase II study determine antitumor activity Vinorelbine Cyclofosfamide association among patient refractory tumour relapse rhabdomyosarcomas soft tissue tumour , Ewing tumour , osteosarcoma , neuroblastomas medulloblastomas .</brief_summary>
	<brief_title>Study Vinorelbine Cyclofosfamide Among Patients With Refractory Tumours Relapse</brief_title>
	<detailed_description />
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Neoplasms , Connective Soft Tissue</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Age &gt; 12 month &lt; 25 year Measurable disease Score Lansky &gt; 30 World Health Organization ( WHO ) score &lt; 2 Life expectancy &gt; 2 month Satisfactory hematologic condition : Polynuclear neutrophiles &gt; 1 X 10^9/l . Platelets &gt; 100 X 10^9/l &gt; 50 X 10^9 event medullary invasion . Creatinine &lt; 1.5 normal age clearance &gt; 70 ml/min/1.73 m2 Normal hepatic function : Bilirubin &lt; 3 N ASAT ALAT &lt; 2,5 N ) . Absence toxicity body ( Rank &gt; 2 accord cod National Cancer InstituteCommon Toxicity Criteria [ NCICTC ] version 2.0 ) Absence antecedent hematuric cystitis repetition Written consent , sign patient two parent holder ( ) parental authority minor subject Does satisfy criterion eligibility</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Soft part tissue</keyword>
</DOC>